Cargando…
Preoperative high dose rate brachytherapy for clinical stage II endometrial carcinoma
PURPOSE: We sought to evaluate pathological response, tolerance, and outcome after preoperative (neoadjuvant) high dose rate brachytherapy in a small series of patients with clinical stage II endometrial carcinoma, and to evaluate a dose and fractionation protocol for this treatment. MATERIAL AND ME...
Autores principales: | Shukla, Gaurav, Beriwal, Sushil, Krivak, Thomas C., Kelley, Joseph L., Sukumvanich, Paniti, Edwards, Robert P., Richard, Scott, Olawaiye, Alexander, Zorn, Kristin K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117533/ https://www.ncbi.nlm.nih.gov/pubmed/27895672 http://dx.doi.org/10.5114/jcb.2011.23200 |
Ejemplares similares
-
High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina
por: Beriwal, Sushil, et al.
Publicado: (2008) -
Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era
por: Berger, Jessica L, et al.
Publicado: (2014) -
Comparison of Locoregional Recurrence with Mastectomy vs. Breast Conserving Surgery in Pregnancy Associated Breast Cancer (PABC)
por: Beriwal, Sushil, et al.
Publicado: (2009) -
Complete Pathologic Response Following Neoadjuvant Chemoradiotherapy and High-Dose-Rate Brachytherapy for Locally Advanced Endometrial Carcinoma
por: Horne, Zachary, et al.
Publicado: (2015) -
Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity
por: Laskey, Robin A, et al.
Publicado: (2014)